1. ALLA AKTIER
  2. NYHETER
  3. AMNIOTICS

Amniotics

Nyheter Amniotics Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Amniotics AB (publ) board member Anders Månsson resigns from the board at his own request

MARKN.

Amniotics AB:s board member Anders Månsson resigns from the board at his own request

Anders Månsson, who has been a board member of Amniotics (publ) since 2017, has today announced that he is leaving the board. This is due to workload, where Anders Månsson will devote his full attention to his new duties as CEO of a Stockholm-based company, he is reducing his board assignments and leaving the Amniotics Board.

"On behalf of the board and the shareholders, I would like to express a big thank you to Anders for his efforts and good cooperation in the work of the board over the past years. I understand that Anders' decision to change the work situation puts obstacles in the way of continued commitment." Says Peter Buhl Jensen, chairman of the board.

About Amniotics

Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid. The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University Hospital of Lund, the company is pioneering the harvesting and propagation of tissue specific neonatal quality mesenchymal stem cells (MSC). These stem cells have unique properties for applications in regenerative medicine. Amniotics has also an, by Läkemedelsverket (Swedish MPA), approved Good Manufacturing Practice (GMP) facility to produce Advanced Therapy Medicinal Products (ATMPs). With the GMP facilities operational since 2020, Amniotics is now moving into clinical trials with the leading drug candidate, PulmoStem™ and is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies targeting diseases with high unmet needs.

Amniotics (publ) has it´s headquarter in Lund, Sweden.

Amniotics Certified Adviser on First North is Redeye AB, certifiedadviser@redeye.se, telephone: +46 (0) 8 121 576 90.

The company is listed at Nasdaq First North Growth Market in Stockholm.

Learn more at www.amniotics.com. 

Attachments

Amniotics AB (publ) board member Anders Månsson resigns from the board at his own request

Datum 2022-08-19, kl 16:30
Källa MFN
Bifogade filer
Amniotics AB (publ) board member Anders Månsson resigns from the board at his own request